Πληροφορίες για την Ατελή Οστεογένεση > Πληροφορίες για την Ατελή Οστεογένεση από το OIF > Διφωσφωνικά > Άρθρα για τη χρήση του Pamidronate στα παιδιά με ατελή οστεογένεση

Άρθρα σχετικά με την ατελή οστεογένεση και τα διφωσφωνικά

1.        Pizones J, Plotkin H, Parra-Garcia JI, Alvarez P, Gutierrez P, Bueno A, Fernandez-Arroyo A.  
Bone Healing in Children With Osteogenesis Imperfecta Treated With Bisphosphonates.
J Pediatr Orthop. 2005 May/June;25(3):332-335.
PMID: 15832149

2.        Gatti D, Antoniazzi F, Prizzi R, Braga V, Rossini M, Tato L, Viapiana O, Adami S.  
Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study.
J Bone Miner Res. 2005 May;20(5):758-63. Epub 2004 Dec 20.
PMID: 15824848

3.        Licata AA.  
Discovery, clinical development, and therapeutic uses of bisphosphonates.
Ann Pharmacother. 2005 Apr;39(4):668-77. Epub 2005 Mar 8.
PMID: 15755793

4.        Dimeglio LA, Ford L, McClintock C, Peacock M.
A comparison of oral and intravenous bisphosphonate therapy for children with osteogenesis imperfecta.
J Pediatr Endocrinol Metab. 2005 Jan;18(1):43-53.
PMID: 15679068 [PubMed - in process]

5.        Waltimo-Siren J, Kolkka M, Pynnonen S, Kuurila K, Kaitila I, Kovero O.  
Craniofacial features in osteogenesis imperfecta: a cephalometric study.
Am J Med Genet A. 2005 Mar 1;133(2):142-50.
PMID: 15666304

6.        Misof BM, Roschger P, Baldini T, Raggio CL, Zraick V, Root L, Boskey AL, Klaushofer K, Fratzl P, Camacho NP.
Differential effects of alendronate treatment on bone from growing osteogenesis imperfecta and wild-type mouse.
Bone. 2005 Jan;36(1):150-8.
PMID: 15664013

7.        Iwamoto J, Takeda T, Sato Y.  
Effect of treatment with alendronate in osteogenesis imperfecta type I: a case report.
Keio J Med. 2004 Dec;53(4):251-5.
PMID: 15647630

8.        Adiyaman P, Ocal G, Berberoglu M, Evliyaoglu O, Aycan Z, Cetinkaya E.  
The clinical and radiological assessment of cyclic intravenous pamidronate administration in children with osteogenesis imperfecta.
Turk J Pediatr. 2004 Oct-Dec;46(4):322-8.
PMID: 15641265

9.        Popko J, Galicka A, Wolczynski S, Zalewski W, Konstantynowicz J.  
[Osteogenesis imperfecta as an interdisciplinary medical problem]
Chir Narzadow Ruchu Ortop Pol. 2004;69(4):235-9. Polish.
PMID: 15587378

10.    Bin-Abbas BS, Al-Ashwal AA, Al-Zayed ZS, Sakati NA.
Radiological features of bisphosphonate therapy in children with osteogenesis imperfecta.
Saudi Med J. 2004 Nov;25(11):1772-3. 
PMID: 15573233

11.    Zacharin M, Kanumakala S.  
 Pamidronate treatment of less severe forms of osteogenesis imperfecta in children.
J Pediatr Endocrinol Metab. 2004 Nov;17(11):1511-7.
PMID: 15570988

12.    Munns CF, Rauch F, Zeitlin L, Fassier F, Glorieux FH.
Delayed osteotomy but not fracture healing in pediatric osteogenesis imperfecta patients receiving pamidronate.
J Bone Miner Res. 2004 Nov;19(11):1779-86. Epub 2004 Aug 23.
PMID: 15476577

13.    Munns CF, Rauch F, Ward L, Glorieux FH.  
Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases.
J Bone Miner Res. 2004 Oct;19(10):1742-5. Epub 2004 Jul 21.
PMID: 15355570

14.    Boutaud B, Laville JM.  
[Elastic sliding central medullary nailing with osteogenesis imperfecta. Fourteen cases at eight years follow-up]
Rev Chir Orthop Reparatrice Appar Mot. 2004 Jun;90(4):304-11. French.
PMID: 15211258

15.    Rauch F, Travers R, Munns C, Glorieux FH.
Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis.
J Bone Miner Res. 2004 Jul;19(7):1191-3. Epub 2004 Jul 1.
PMID: 15177003

16.    Sakkers R, Kok D, Engelbert R, van Dongen A, Jansen M, Pruijs H, Verbout A, Schweitzer D, Uiterwaal C.  
Skeletal effects and functional outcome with olpadronate in children
with osteogenesis imperfecta: a 2-year randomised placebo-controlled
study.
Lancet. 2004 May 1;363(9419):1427-31.
PMID: 15121405

17.    Rauch F, Glorieux FH.  
Osteogenesis imperfecta.
Lancet. 2004 Apr 24;363(9418):1377-85. 
PMID: 15110498

18.    Arikoski P, Silverwood B, Tillmann V, Bishop NJ.
Intravenous pamidronate treatment in children with moderate to
severe osteogenesis imperfecta: assessment of indices of dual-energy
X-ray absorptiometry and bone metabolic markers during the first year
of therapy.
Bone. 2004 Mar;34(3):539-46.
PMID: 15003801

19.    Robinson RE, Nahata MC, Hayes JR, Batisky DL, Bates CM, Mahan JD.  
Effectiveness of pretreatment in decreasing adverse events associated with pamidronate in children and adolescents.
Pharmacotherapy. 2004 Feb;24(2):195-7.
PMID: 14998220

20.    Niyibizi C, Wang S, Mi Z, Robbins PD.  
Gene therapy approaches for osteogenesis imperfecta.
Gene Ther. 2004 Feb;11(4):408-16. 
PMID: 14724682

21.    Glorieux FH, Rauch F, Shapiro JR.  
Bisphosphonates in children with bone diseases.
N Engl J Med. 2003 Nov 20;349(21):2068-71; author reply 2068-71.
PMID: 14631922

22.    Plotkin H.  
Bisphosphonates in children with bone diseases.
N Engl J Med. 2003 Nov 20;349(21):2068-71; author reply 2068-71.
PMID: 14627793

23.    Tolboom N, Cats EA, Helders PJ, Pruijs JE, Engelbert RH.
Osteogenesis imperfecta in childhood: effects of spondylodesis on
functional ability, ambulation and perceived competence.
Eur Spine J. 2004 Mar;13(2):108-13. Epub 2003 Nov 8.
PMID: 14608498

24.    Ashford RU, Dey A, Kayan K, McCloskey EV, Kanis JA.
Oral clodronate as treatment of osteogenesis imperfecta.
Arch Dis Child. 2003 Oct;88(10):945. 
PMID: 14500323

25.    Davies JH, Gregory JW.  
Radiographic long bone appearance in a child administered cyclical pamidronate.
Arch Dis Child. 2003 Oct;88(10):854. 
PMID: 14500300

26.    Kok DJ, Uiterwaal CS, Van Dongen AJ, Kramer PP, Pruijs HE, Engelbert RH, Verbout AJ, Schweitzer DH, Sakkers RJ.
The interaction between Sillence type and BMD in osteogenesis imperfecta.
Calcif Tissue Int. 2003 Nov;73(5):441-5. Epub 2003 Sep 10.
PMID: 12958692

27.    Marini JC.  
Do bisphosphonates make children's bones better or brittle?
N Engl J Med. 2003 Jul 31;349(5):423-6. 
PMID: 12890840

28.    Reid IR.  
Bisphosphonates: new indications and methods of administration.
Curr Opin Rheumatol. 2003 Jul;15(4):458-63. 
PMID: 12819475

29.    Maasalu K, Haviko T, Martson A.  
Treatment of children with Osteogenesis imperfecta in Estonia.
Acta Paediatr. 2003 Apr;92(4):452-5.
PMID: 12801112

30.    Montpetit K, Plotkin H, Rauch F, Bilodeau N, Cloutier S, Rabzel
M, Glorieux FH.  
Rapid increase in grip force after start of pamidronate therapy in children and adolescents with severe osteogenesis imperfecta.
Pediatrics. 2003 May;111(5 Pt 1):e601-3.
PMID: 12728117

31.    Zeitlin L, Rauch F, Plotkin H, Glorieux FH.
Height and weight development during four years of therapy with cyclical intravenous pamidronate in children and adolescents with osteogenesis imperfecta types I, III, and IV.
Pediatrics. 2003 May;111(5 Pt 1):1030-6.
PMID: 12728084

32.    Grissom LE, Harcke HT.  
Radiographic features of bisphosphonate therapy in pediatric patients.
Pediatr Radiol. 2003 Apr;33(4):226-9. Epub 2003 Feb 15.
PMID: 12709749

33.    Rauch F, Plotkin H, Zeitlin L, Glorieux FH.
Bone mass, size, and density in children and adolescents with osteogenesis imperfecta: effect of intravenous pamidronate therapy.
J Bone Miner Res. 2003 Apr;18(4):610-4.
PMID: 12674321

34.    Evans KD, Lau ST, Oberbauer AM, Martin RB.
Alendronate affects long bone length and growth plate morphology in the oim mouse model for Osteogenesis Imperfecta.
Bone. 2003 Mar;32(3):268-74.
PMID: 12667554

35.    Iwamoto J, Matsu K, Takeda T, Ichimura S, Uzawa M.
Effects of treatment with etidronate and alfacalcidol for osteogenesis imperfecta type I: a case report.
J Orthop Sci. 2003;8(2):243-7.
PMID: 12665966

36.    Chien YH, Chu SY, Hsu CC, Hwu WL.  
Pamidronate treatment of severe osteogenesis imperfecta in a newborn infant.
J Inherit Metab Dis. 2002 Nov;25(7):593-5.  
PMID: 12638943

37.    Rauch F, Plotkin H, Travers R, Zeitlin L, Glorieux FH.
Osteogenesis imperfecta types I, III, and IV: effect of pamidronate therapy on bone and mineral metabolism.
J Clin Endocrinol Metab. 2003 Mar;88(3):986-92.
PMID: 12629073

38.    Langman CB.  
Improvement of bone in patients with osteogenesis imperfecta treated with pamidronate-lessons from biochemistry.
J Clin Endocrinol Metab. 2003 Mar;88(3):984-5. 
PMID: 12629072

39.    Falk MJ, Heeger S, Lynch KA, DeCaro KR, Bohach D, Gibson KS, Warman ML.  
Intravenous bisphosphonate therapy in children with osteogenesis imperfecta.
Pediatrics. 2003 Mar;111(3):573-8.
PMID: 12612238

40.    Batch JA, Couper JJ, Rodda C, Cowell CT, Zacharin M.
Use of bisphosphonate therapy for osteoporosis in childhood and
adolescence.
J Paediatr Child Health. 2003 Mar;39(2):88-92. 
PMID: 12603794

41.    Illum NO.  
[Bisphosphonate treatment of children and adolescents]
Ugeskr Laeger. 2003 Jan 27;165(5):454-6. Danish.
PMID: 12599842

42.    Zeitlin L, Fassier F, Glorieux FH.  
Modern approach to children with osteogenesis imperfecta.
J Pediatr Orthop B. 2003 Mar;12(2):77-87. 
PMID: 12584489

43.    Camacho NP, Carroll P, Raggio CL.  
Fourier transform infrared imaging spectroscopy (FT-IRIS) of mineralization in bisphosphonate-treated oim/oim mice.
Calcif Tissue Int. 2003 May;72(5):604-9. Epub 2003 Feb 10.
PMID: 12574874

44.    Yurekli Y, Erdogan S, Cullu E.  
Unusual bone scan of a child with osteogenesis imperfecta.
Clin Nucl Med. 2003 Feb;28(2):156. 
PMID: 12544144

45.    Adami S, Gatti D, Colapietro F, Fracassi E, Braga V, Rossini M, Tato L.  
Intravenous neridronate in adults with osteogenesis imperfecta.
J Bone Miner Res. 2003 Jan;18(1):126-30.
PMID: 12510813

46.    Devogelaer JP.  
New uses of bisphosphonates: osteogenesis imperfecta.
Curr Opin Pharmacol. 2002 Dec;2(6):748-53. 
PMID: 12482741

47.    Giraud F, Meunier PJ. 
Effect of cyclical intravenous pamidronate therapy in children with osteogenesis imperfecta. Open-label study in seven patients.
Joint Bone Spine. 2002 Oct;69(5):486-90.
PMID: 12477233

48.    Shapiro JR, McCarthy EF, Rossiter K, Ernest K, Gelman R, Fedarko N, Santiago HT, Bober M.  
The effect of intravenous pamidronate on bone mineral density, bone histomorphometry, and parameters of bone turnover in adults with type IA osteogenesis imperfecta.
Calcif Tissue Int. 2003 Feb;72(2):103-12. Epub 2002 Dec 4.
PMID: 12457260

49.    Banerjee I, Shortland GJ, Evans WD, Gregory JW.
Osteogenesis imperfecta and intravenous pamidronate.
Arch Dis Child. 2002 Dec;87(6):562-3. 
PMID: 12456578

50.    Rauch F, Travers R, Plotkin H, Glorieux FH.
The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta.
J Clin Invest. 2002 Nov;110(9):1293-9.
PMID: 12417568

51.    Lindsay R.  
Modeling the benefits of pamidronate in children with osteogenesis imperfecta.
J Clin Invest. 2002 Nov;110(9):1239-41. 
PMID: 12417561

52.    McCarthy EA, Raggio CL, Hossack MD, Miller EA, Jain S, Boskey AL, Camacho NP.
Alendronate treatment for infants with osteogenesis imperfecta: demonstration of efficacy in a mouse model.
Pediatr Res. 2002 Nov;52(5):660-70.
PMID: 12409511

53.    Kone Paut I, Gennari JM, Retornaz K, Jouve JL, Bollini G.
[Biphosphonates in children: present and future]
Arch Pediatr. 2002 Aug;9(8):836-42.  French. Erratum in: Arch
Pediatr. 2002 Dec;9(12):1301.
PMID: 12205795

54.    Allgrove J.  
Use of bisphosphonates in children and adolescents.
J Pediatr Endocrinol Metab. 2002;15 Suppl 3:921-8. 
PMID: 12199351

55.    Kaitila I, Kuurila K, Kallio P.  
[Osteogenesis imperfecta--a congenital brittleness of bones]
Duodecim. 2001;117(21):2195-202.  Finnish.
PMID: 12184207

56.    Silverwood B.  
Osteogenesis imperfecta: care and management.
Paediatr Nurs. 2001 Apr;13(3):38-42.
PMID: 12025296

57.    Inoue N, Seino Y.  
[Osteoporosis in childhood]
Nippon Rinsho. 2002 Mar;60 Suppl 3:315-22.  Japanese.
PMID: 11979924

58.    Astrom E, Soderhall S.  
Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.
Arch Dis Child. 2002 May;86(5):356-64.
PMID: 11970931

59.    Zacharin M, Bateman J.  
Pamidronate treatment of osteogenesis imperfecta--lack of correlation between clinical severity, age at onset of treatment, predicted collagen mutation and treatment response.
J Pediatr Endocrinol Metab. 2002 Feb;15(2):163-74.
PMID: 11874181

60.    Orcel P, Beaudreuil J.  
Bisphosphonates in bone diseases other than osteoporosis.
Joint Bone Spine. 2002 Jan;69(1):19-27. 
PMID: 11858352

61.    Glorieux FH.  
The use of bisphosphonates in children with osteogenesis imperfecta.
J Pediatr Endocrinol Metab. 2001;14 Suppl 6:1491-5. 
PMID: 11837505

62.    Lee YS, Low SL, Lim LA, Loke KY.  
Cyclic pamidronate infusion improves bone mineralisation and reduces fracture incidence in osteogenesis imperfecta.
Eur J Pediatr. 2001 Nov;160(11):641-4.
PMID: 11760017

63.    Vasikaran SD.  
Bisphosphonates: an overview with special reference to alendronate.
Ann Clin Biochem. 2001 Nov;38(Pt 6):608-23. 
PMID: 11732644

64.    Camacho NP, Raggio CL, Doty SB, Root L, Zraick V, Ilg WA, Toledano TR, Boskey AL.  
A controlled study of the effects of alendronate in a growing mouse model of osteogenesis imperfecta.
Calcif Tissue Int. 2001 Aug;69(2):94-101.
PMID: 11683430

65.    Primorac D, Rowe DW, Mottes M, Barisic I, Anticevic D, Mirandola
S, Gomez Lira M, Kalajzic I, Kusec V, Glorieux FH.
Osteogenesis imperfecta at the beginning of boneand joint decade.
Croat Med J. 2001 Aug;42(4):393-415. 
PMID: 11471191

66.    Gonzalez E, Pavia C, Ros J, Villaronga M, Valls C, Escola J.
Efficacy of low dose schedule pamidronate infusion in children with osteogenesis imperfecta.
J Pediatr Endocrinol Metab. 2001 May;14(5):529-33.
PMID: 11393574

67.    Chevrel G, Meunier PJ.  
Osteogenesis imperfecta: lifelong management is imperative and feasible.
Joint Bone Spine. 2001 Mar;68(2):125-9.  
PMID: 11324928

68.    Guillot M, Eckart P, Desrosieres H, Amiour M, al-Jazayri Z.
[Osteogenesis imperfecta: a new, early therapeutic approach with biphosphonates. A case report]
Arch Pediatr. 2001 Feb;8(2):172-5. French.
PMID: 11232458

69.    Smith R.  
Severe osteogenesis imperfecta: new therapeutic options?
BMJ. 2001 Jan 13;322(7278):63-64. 
PMID: 11154605

70.    Antoniazzi F, Mottes M, Fraschini P, Brunelli PC, Tato L.
Osteogenesis imperfecta: practical treatment guidelines.
Paediatr Drugs. 2000 Nov-Dec;2(6):465-88. 
PMID: 11127846

71.    Byers PH.  
Osteogenesis imperfecta: perspectives and opportunities.
Curr Opin Pediatr. 2000 Dec;12(6):603-9. 
PMID: 11106283

72.    Glorieux FH.  
Bisphosphonate therapy for severe osteogenesis imperfecta.
J Pediatr Endocrinol Metab. 2000 Sep;13 Suppl 2:989-92.
PMID: 11086652

73.    Devogelaer JP.  
Treatment of bone diseases with bisphosphonates, excluding osteoporosis.
Curr Opin Rheumatol. 2000 Jul;12(4):331-5. 
PMID: 10910187

74.    Plotkin H, Rauch F, Bishop NJ, Montpetit K, Ruck-Gibis J, Travers R, Glorieux FH.  
Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age.
J Clin Endocrinol Metab. 2000 May;85(5):1846-50.
PMID: 10843163

75.    Krassas GE.  
Idiopathic juvenile osteoporosis.
Ann N Y Acad Sci. 2000;900:409-12.
PMID: 10818429

76.    Srivastava T, Alon US.  
Bisphosphonates: from grandparents to grandchildren.
Clin Pediatr (Phila). 1999 Dec;38(12):687-702. 
PMID: 10618761

77.    Roldan EJ, Pasqualini T, Plantalech L.  
Bisphosphonates in children with osteogenesis imperfecta may improve bone mineralization but not bone strength. Report of two patients.
J Pediatr Endocrinol Metab. 1999 Jul-Aug;12(4):555-9.
PMID: 10417973

78.    Bishop NJ.  
Osteogenesis imperfecta calls for caution.
Nat Med. 1999 May;5(5):466-7. 
PMID: 10229208

79.    Marini JC.  
Osteogenesis imperfecta--managing brittle bones.
N Engl J Med. 1998 Oct 1;339(14):986-7. 
PMID: 9753715

80.    Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R.  
Cyclic administration of pamidronate in children with severe osteogenesis imperfecta.
N Engl J Med. 1998 Oct 1;339(14):947-52.
PMID: 9753709

81.    Devogelaer JP, Nagant de Deuxchaisnes C.
Use of pamidronate in chronic and acute bone loss conditions.
Medicina (B Aires). 1997;57 Suppl 1:101-8.
PMID: 9567362

82.    Kodama H, Kubota K, Abe T.  
Osteogenesis imperfecta: Are fractures and growth hormone treatment linked?
J Pediatr. 1998 Mar;132(3 Pt 1):559-60. 
PMID: 9544925

83.    Fujiwara I, Ogawa E, Igarashi Y, Ohba M, Asanuma A.
Intravenous pamidronate treatment in osteogenesis imperfecta.
Eur J Pediatr. 1998 Mar;157(3):261-2. 
PMID: 9537501

84.    Astrom E, Soderhall S.  
Beneficial effect of bisphosphonate during five years of treatment of severe osteogenesis imperfecta.
Acta Paediatr. 1998 Jan;87(1):64-8.
PMID: 9510450

85.    Bembi B, Parma A, Bottega M, Ceschel S, Zanatta M, Martini C, Ciana G.  
Intravenous pamidronate treatment in osteogenesis imperfecta.
J Pediatr. 1997 Oct;131(4):622-5.
PMID: 9386671

86.    Landsmeer-Beker EA, Massa GG, Maaswinkel-Mooy PD, van de Kamp JJ, Papapoulos SE.  
Treatment of osteogenesis imperfecta with the bisphosphonate olpadronate (dimethylaminohydroxypropylidene bisphosphonate).
Eur J Pediatr. 1997 Oct;156(10):792-4.
PMID: 9365071

87.    Moriwake T, Seino Y.  
Recent progress in diagnosis and treatment of osteogenesis imperfecta.
Acta Paediatr Jpn. 1997 Aug;39(4):521-7. 
PMID: 9316304

88.    Brumsen C, Hamdy NA, Papapoulos SE.  
Long-term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis.
Medicine (Baltimore). 1997 Jul;76(4):266-83. 
PMID: 9279333

89.    Shaw NJ.  
Bisphosphonates in osteogenesis imperfecta.
Arch Dis Child. 1997 Jul;77(1):92-3. 
PMID: 9279168

90.    Chevrel G, Meunier PJ.  
Are drugs helpful in adults with osteogenesis imperfecta?
Rev Rhum Engl Ed. 1997 May;64(5):283-6. 
PMID: 9190000

91.    Williams CJ, Smith RA, Ball RJ, Wilkinson H.
Hypercalcaemia in osteogenesis imperfecta treated with pamidronate.
Arch Dis Child. 1997 Feb;76(2):169-70.
PMID: 9068314

92.    Cherie-Ligniere G, Tamborini U, Grosso P.
Algodystrophy in conjunction with van der Hoeve's syndrome.
Clin Exp Rheumatol. 1995 May-Jun;13(3):361-5.
PMID: 7554566

93.    Laroche M, Dromer C, Jacquemier JM, Mazieres B, Arlet J.
[The association of algodystrophy and Lobstein's disease. Possible value of 3-amino-1-hydroxypropane-1,1-diphosphonic acid]
Rev Rhum Mal Osteoartic. 1990 Mar;57(3):221-2. French.
PMID: 2339269

94.    Burke TE, Crerand SJ, Dowling F.  
Hypertrophic callus formation leading to high-output cardiac failure in a patient with osteogenesis imperfecta.
J Pediatr Orthop. 1988 Sep-Oct;8(5):605-8.
PMID: 3170743

95.    Huaux JP, Lokietek W.  
Is APD a promising drug in the treatment of severe osteogenesis imperfecta?
J Pediatr Orthop. 1988 Jan-Feb;8(1):71-2.
PMID: 3335625

96.    Devogelaer JP, Malghem J, Maldague B, Nagant de Deuxchaisnes C.
Radiological manifestations of bisphosphonate treatment with APD in a child suffering from osteogenesis imperfecta.
Skeletal Radiol. 1987;16(5):360-3.
PMID: 3629280

97.    Kramer EL, Rafii M, Fazzini E, Sanger J.
Bone scan appearance of osteogenesis imperfecta in an adult.
Clin Nucl Med. 1986 May;11(5):331-3.
PMID: 3698431

4Δείτε επίσης: Abstracts από μερικά άρθρα για τη χρήση του Pamidronate στα παιδιά με ατελή οστεογένεση